Logo image of PAVM

PAVMED INC (PAVM) Stock Fundamental Analysis

USA - NASDAQ:PAVM - US70387R4039 - Common Stock

0.4355 USD
0 (-1.07%)
Last: 10/3/2025, 8:00:02 PM
0.441 USD
+0.01 (+1.26%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, PAVM scores 4 out of 10 in our fundamental rating. PAVM was compared to 191 industry peers in the Health Care Equipment & Supplies industry. PAVM may be in some trouble as it scores bad on both profitability and health. PAVM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PAVM was profitable.
In the past year PAVM has reported a negative cash flow from operations.
PAVM had negative earnings in 4 of the past 5 years.
PAVM had a negative operating cash flow in each of the past 5 years.
PAVM Yearly Net Income VS EBIT VS OCF VS FCFPAVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of PAVM (159.59%) is better than 100.00% of its industry peers.
PAVM has a Return On Equity of 171.73%. This is amongst the best in the industry. PAVM outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 159.59%
ROE 171.73%
ROIC N/A
ROA(3y)-87.06%
ROA(5y)-98.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PAVM Yearly ROA, ROE, ROICPAVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

PAVM has a Profit Margin of 6867.55%. This is amongst the best in the industry. PAVM outperforms 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for PAVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 6867.55%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PAVM Yearly Profit, Operating, Gross MarginsPAVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

PAVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PAVM has been increased compared to 1 year ago.
PAVM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PAVM has been reduced compared to a year ago.
PAVM Yearly Shares OutstandingPAVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PAVM Yearly Total Debt VS Total AssetsPAVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.34, we must say that PAVM is in the distress zone and has some risk of bankruptcy.
PAVM has a Altman-Z score of -8.34. This is in the lower half of the industry: PAVM underperforms 76.96% of its industry peers.
PAVM has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
PAVM's Debt to Equity ratio of 0.17 is in line compared to the rest of the industry. PAVM outperforms 58.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z -8.34
ROIC/WACCN/A
WACC6.1%
PAVM Yearly LT Debt VS Equity VS FCFPAVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

PAVM has a Current Ratio of 0.52. This is a bad value and indicates that PAVM is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.52, PAVM is not doing good in the industry: 92.67% of the companies in the same industry are doing better.
PAVM has a Quick Ratio of 0.52. This is a bad value and indicates that PAVM is not financially healthy enough and could expect problems in meeting its short term obligations.
PAVM's Quick ratio of 0.52 is on the low side compared to the rest of the industry. PAVM is outperformed by 91.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.52
PAVM Yearly Current Assets VS Current LiabilitesPAVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

PAVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.58%, which is quite impressive.
Looking at the last year, PAVM shows a very negative growth in Revenue. The Revenue has decreased by -73.35% in the last year.
Measured over the past years, PAVM shows a very strong growth in Revenue. The Revenue has been growing by 81.61% on average per year.
EPS 1Y (TTM)116.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.82%
Revenue 1Y (TTM)-73.35%
Revenue growth 3Y81.61%
Revenue growth 5YN/A
Sales Q2Q%-99.39%

3.2 Future

PAVM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.79% yearly.
The Revenue is expected to grow by 142.05% on average over the next years. This is a very strong growth
EPS Next Y108.83%
EPS Next 2Y26.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-96.01%
Revenue Next 2Y-63.49%
Revenue Next 3Y268.29%
Revenue Next 5Y142.05%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PAVM Yearly Revenue VS EstimatesPAVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
PAVM Yearly EPS VS EstimatesPAVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10 -15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.33, the valuation of PAVM can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of PAVM indicates a rather cheap valuation: PAVM is cheaper than 100.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.86. PAVM is valued rather cheaply when compared to this.
PAVM is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.33
Fwd PE N/A
PAVM Price Earnings VS Forward Price EarningsPAVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PAVM Per share dataPAVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PAVM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PAVM's earnings are expected to grow with 26.79% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y26.79%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PAVM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAVMED INC

NASDAQ:PAVM (10/3/2025, 8:00:02 PM)

After market: 0.441 +0.01 (+1.26%)

0.4355

0 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11
Inst Owners10.64%
Inst Owner Change0%
Ins Owners4.91%
Ins Owner Change15.5%
Market Cap9.25M
Analysts82.5
Price Target11.73 (2593.46%)
Short Float %2.53%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.83%
Min EPS beat(2)-458.07%
Max EPS beat(2)356.41%
EPS beat(4)2
Avg EPS beat(4)4.93%
Min EPS beat(4)-458.07%
Max EPS beat(4)356.41%
EPS beat(8)4
Avg EPS beat(8)-2.84%
EPS beat(12)7
Avg EPS beat(12)1.55%
EPS beat(16)7
Avg EPS beat(16)-3.09%
Revenue beat(2)0
Avg Revenue beat(2)-31.37%
Min Revenue beat(2)-41.18%
Max Revenue beat(2)-21.57%
Revenue beat(4)0
Avg Revenue beat(4)-42.93%
Min Revenue beat(4)-98.31%
Max Revenue beat(4)-10.67%
Revenue beat(8)1
Avg Revenue beat(8)-22.75%
Revenue beat(12)2
Avg Revenue beat(12)-30.74%
Revenue beat(16)2
Avg Revenue beat(16)-36.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.25%
EPS NY rev (1m)0%
EPS NY rev (3m)131.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-66.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.33
Fwd PE N/A
P/S 9.07
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.23
EV/EBITDA N/A
EPS(TTM)1.33
EY305.4%
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.05
BVpS1.92
TBVpS1.92
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 159.59%
ROE 171.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 6867.55%
GM N/A
FCFM N/A
ROA(3y)-87.06%
ROA(5y)-98.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.45%
Cap/Sales 2.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.52
Altman-Z -8.34
F-Score4
WACC6.1%
ROIC/WACCN/A
Cap/Depr(3y)25.15%
Cap/Depr(5y)202.92%
Cap/Sales(3y)138.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.82%
EPS Next Y108.83%
EPS Next 2Y26.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-73.35%
Revenue growth 3Y81.61%
Revenue growth 5YN/A
Sales Q2Q%-99.39%
Revenue Next Year-96.01%
Revenue Next 2Y-63.49%
Revenue Next 3Y268.29%
Revenue Next 5Y142.05%
EBIT growth 1Y54.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.3%
OCF growth 3YN/A
OCF growth 5YN/A